Top

International Journal of Clinical Oncology

Published in:

01-08-2017 | Original Article

The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis

Authors: Ding Ye, Danjie Jiang, Yingjun Li, Mingjuan Jin, Kun Chen

Published in: International Journal of Clinical Oncology | Issue 4/2017

Abstract

Background

The prognostic value of long interspersed nucleotide element-1 (LINE-1) methylation in patients with colorectal cancer (CRC) remains uncertain. We have therefore performed a meta-analysis to elucidate this issue.

Methods

The PubMed and Web of Science databases were searched for studies published up to 30 June 2016 which reported on an association between LINE-1 methylation and overall survival (OS), disease-free survival (DFS), or cancer-specific survival (CSS) among CRC patients. The reference lists of the identified studies were also analyzed to identify additional eligible studies. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using the fixed-effects or the random-effects model. Stratification analysis and meta-regression analysis were performed to detect the source of heterogeneity. Analyses of sensitivity and publication bias were also carried out.

Results

Thirteen independent studies involving 3620 CRC patients were recruited to the meta-analysis. LINE-1 hypomethylation was found to be significantly associated with shorter OS (HR 2.92, 95% CI 2.20–3.88, p < 0.001) and DFS (HR 2.18, 95% CI 1.46–3.27, p < 0.001), as well as unfavorable CSS (HR 1.96, 95% CI 1.35–2.85, p < 0.001). No heterogeneity was found among the studies evaluating the associations between LINE-1 hypomethylation and OS or DFS, with the exception being CSS. Moreover, meta-regression analysis suggested that one of the contributors to between-study heterogeneity on the association between LINE-1 methylation and CSS was statistical methodology. The subgroup analysis suggested that the association in studies using the Cox model statistical method (HR 2.76, 95% CI 1.90–4.01, p < 0.001) was stronger than that in studies using the Log-rank test (HR 1.41, 95% CI 1.07–1.87, p = 0.015).

Conclusions

The results of this meta-analysis suggest that LINE-1 methylation is significantly associated with the survival of CRC patients and that it could be a predictive factor for CRC prognosis.

Available only for authorised users

Lavie L, Maldener E, Brouha B et al (2004) The human L1 promoter: variable transcription initiation sites and a major impact of upstream flanking sequence on promoter activity. Genome Res 14(11):2253–2260. doi:10.1101/gr.2745804 CrossRefPubMedPubMedCentral

Brouha B, Schustak J, Badge RM et al (2003) Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci USA 100(9):5280–5285. doi:10.1073/pnas.0831042100 CrossRefPubMedPubMedCentral

Sassaman DM, Dombroski BA, Moran JV et al (1997) Many human L1 elements are capable of retrotransposition. Nat Genet 16(1):37–43. doi:10.1038/Ng0597-37 CrossRefPubMed

Steinhoff C, Schulz WA (2004) Transcriptional regulation of the human LINE-1 retrotransposon L1.2B. Mol Genet Genomics 270(5):394–402. doi:10.1007/s00438-003-0931-2 CrossRef

Meissner A (2010) Epigenetic modifications in pluripotent and differentiated cells. Nat Biotechnol 28(10):1079–1088. doi:10.1038/nbt1684 CrossRefPubMed

Barlow DP (2011) Genomic imprinting: a mammalian epigenetic discovery model. Annu Rev Genet 45:379–403. doi:10.1146/annurev-genet-110410-132459 CrossRefPubMed

Martin M, Herceg Z (2012) From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med 4:8. doi:10.1186/gm307 CrossRefPubMedPubMedCentral

Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11(10):726–734. doi:10.1038/nrc3130 CrossRefPubMedPubMedCentral

Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447(7143):433–440. doi:10.1038/nature05919 CrossRefPubMed

10.

Yang AS, Estecio MRH, Doshi K et al (2004) A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 32(3):e38. doi:10.1093/nar/gnh032 CrossRefPubMedPubMedCentral

11.

Harada K, Baba Y, Ishimoto T et al (2015) LINE-1 methylation level and patient prognosis in a database of 208 hepatocellular carcinomas. Ann Surg Oncol 22(4):1280–1287. doi:10.1245/s10434-014-4134-3 CrossRefPubMed

12.

Ikeda K, Shiraishi K, Eguchi A et al (2013) Long interspersed nucleotide element 1 hypomethylation is associated with poor prognosis of lung adenocarcinoma. Ann Thorac Surg 96(5):1790–1795. doi:10.1016/j.athoracsur.2013.06.035 CrossRefPubMed

13.

Cash HL, Tao L, Yuan JM et al (2012) LINE-1 hypomethylation is associated with bladder cancer risk among nonsmoking Chinese. Int J Cancer 130(5):1151–1159. doi:10.1002/ijc.26098 CrossRefPubMed

14.

Baba Y, Huttenhower C, Nosho K et al (2010) Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 9:125. doi:10.1186/1476-4598-9-125 CrossRefPubMedPubMedCentral

15.

Tang JT, Wang ZH, Fang JY (2015) Assessing the potential value of long interspersed element-1 hypomethylation in colorectal cancer: evidence from retrospective studies. Oncotargets Ther 8:3265–3276. doi:10.2147/Ott.S91941 CrossRef

16.

Gallois C, Laurent-Puig P, Taieb J (2016) Methylator phenotype in colorectal cancer: a prognostic factor or not? Crit Rev Oncol Hemat 99:74–80. doi:10.1016/j.critrevonc.2015.11.001 CrossRef

17.

Ogino S, Nosho K, Kirkner GJ (2008) A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 100(23):1734–1738. doi:10.1093/jnci/djn359 CrossRefPubMedPubMedCentral

18.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34. doi:10.1016/j.jclinepi.2009.06.006 CrossRefPubMed

19.

McShane LM, Altman DG, Sauerbrei W (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391. doi:10.1038/sj.bjc.6602678 CrossRefPubMedPubMedCentral

20.

Tierney JF, Stewart LA, Ghersi D (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16 CrossRefPubMedPubMedCentral

21.

Altman DG, Bland JM (2011) How to obtain the confidence interval from a P value. BMJ 343:d2090. doi:10.1136/bmj.d2090 CrossRefPubMed

22.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186 CrossRefPubMed

23.

Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. doi:10.1136/bmj.327.7414.557 CrossRefPubMedPubMedCentral

24.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed

25.

Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1–30CrossRefPubMed

26.

Hayashino Y, Noguchi Y, Fukui T (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15(6):235–243CrossRefPubMed

27.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed

28.

Ahn JB, Chung WB, Maeda O et al (2011) DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117(9):1847–1854. doi:10.1002/cncr.25737 CrossRefPubMed

29.

Antelo M, Balaguer F, Shia J et al (2012) A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One 7(9):e45357. doi:10.1371/journal.pone.0045357 CrossRefPubMedPubMedCentral

30.

Benard A, van de Velde CJH, Lessard L et al (2013) Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. Br J Cancer 109(12):3073–3083. doi:10.1038/bjc.2013.654 CrossRefPubMedPubMedCentral

31.

Chen D, Wen X, Song YS et al (2016) Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients. Clin Epigenetics 8:36. doi:10.1186/s13148-016-0203-8 CrossRefPubMedPubMedCentral

32.

Kawakami K, Matsunoki A, Kaneko M et al (2011) Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci 102(1):166–174. doi:10.1111/j.1349-7006.2010.01776.x CrossRefPubMed

33.

Lou YT, Chen CW, Fan YC et al (2015) LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy. PLoS One 10(4):1011. doi:10.1371/journal.pone.0123973 CrossRef

34.

Mima K, Nowak JA, Qian ZR et al (2016) Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget. doi:10.18632/oncotarget.10398

35.

Murata A, Baba Y, Watanabe M et al (2013) Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. Br J Cancer 109(2):408–415. doi:10.1038/bjc.2013.289 CrossRefPubMedPubMedCentral

36.

Naito T, Nosho K, Ito M et al (2014) IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. World J Gastroentero 20(29):10050–10061. doi:10.3748/wjg.v20.i29.10050 CrossRef

37.

Rhee YY, Kim MJ, Bae JM et al (2012) Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level. Ann Surg Oncol 19(11):3441–3448. doi:10.1245/s10434-012-2410-7 CrossRefPubMed

38.

Sahnane N, Magnoli F, Bernasconi B et al (2015) Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. Clin Epigenetics 7:131. doi:10.1186/s13148-015-0165-2 CrossRefPubMedPubMedCentral

39.

Zhuo CH, Li QG, Wu YC et al (2015) LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer. Oncotarget 6(27):23820–23836. doi:10.18632/oncotarget.4450 CrossRefPubMedPubMedCentral

40.

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed

41.

Grade M, Becker H, Liersch T et al (2006) Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cell Oncol 28(3):71–84PubMedPubMedCentral

42.

Levin B, Lieberman DA, McFarland B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5):1570–1595. doi:10.1053/j.gastro.2008.02.002 CrossRefPubMed

43.

Juo YY, Johnston FM, Zhang DY et al (2014) Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol 25(12):2314–2327. doi:10.1093/annonc/mdu149 CrossRefPubMedPubMedCentral

44.

Jiang W, Wang PG, Zhan Y et al (2014) Prognostic value of p16 promoter hypermethylation in colorectal cancer: a meta-analysis. Cancer Invest 32(2):43–52. doi:10.3109/07357907.2013.861476 CrossRefPubMed

45.

Xing X, Cai W, Shi H et al (2013) The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer 108(12):2542–2548. doi:10.1038/bjc.2013.251 CrossRefPubMedPubMedCentral

46.

Li Y, Lyu Z, Zhao L et al (2015) Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review. Tumour Biol 36(3):1595–1601. doi:10.1007/s13277-014-2752-9 CrossRefPubMed

47.

Estecio MRH, Gharibyan V, Shen LL et al (2007) LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2(5):e399. doi:10.1371/journal.pone.0000399 CrossRefPubMedPubMedCentral

48.

Ogino S, Kawasaki T, Nosho K et al (2008) LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 122(12):2767–2773. doi:10.1002/ijc.23470 CrossRefPubMedPubMedCentral

Title: The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis
Authors: Ding Ye
Danjie Jiang
Yingjun Li
Mingjuan Jin
Kun Chen
Publication date: 01-08-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1106-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer

Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan

Targeting metabolic reprogramming in KRAS-driven cancers

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

Biphasic malignant tumours of the abdominal cavity

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer